WILMINGTON, Del.–AstraZeneca has received U.S. Food and Drug Administration approval for a new combination treatment for muscle-invasive bladder cancer following clinical trial results showing a 42% reduction in the risk of death and a 49% reduction in the risk of disease progression, recurrence or other events.
The approval covers the use of AstraZeneca’s immunotherapy drug IMFINZI (durvalumab) in combination with enfortumab vedotin-ejfv (EV) before surgery, followed by IMFINZI alone after bladder removal.
The treatment is intended for adults with muscle-invasive bladder cancer who are unable to receive or have declined cisplatin-based chemotherapy.
The FDA granted approval following a Priority Review based on findings from the Phase 3 VOLGA clinical trial. Results were presented at the 2026 European Society for Medical Oncology Congress and simultaneously published in The New England Journal of Medicine.
Muscle-invasive bladder cancer develops when a tumor penetrates the muscular wall of the bladder. Approximately one-quarter of bladder cancer patients have this form of the disease, and about 16,000 patients are expected to receive treatment for it in the United States during 2026.
As many as half of these patients are unable to receive cisplatin-based chemotherapy because of kidney problems or other medical conditions.
For such patients, surgical removal of the bladder has historically been the primary treatment option. However, recurrence remains a significant concern even after surgery.
The newly approved regimen combines immunotherapy with an antibody-drug conjugate before surgery to help control the cancer, followed by additional immunotherapy intended to reduce the likelihood of recurrence.
Dr. Jonathan E. Rosenberg, Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center and a member of the VOLGA Steering Committee, said the approval introduces an additional treatment option for patients who cannot receive conventional chemotherapy.
“This approval brings the first perioperative immunotherapy regimen where enfortumab vedotin-ejfv is administered only in the neoadjuvant setting to patients with muscle-invasive bladder cancer who are not candidates for cisplatin-based chemotherapy. The results of VOLGA show a statistically significant and clinically meaningful improvement in both event-free and overall survival along with a manageable safety profile. Based on this, the VOLGA regimen has the potential to become a new standard of care in this curative-intent setting.”
During the VOLGA trial, patients received three cycles of IMFINZI combined with enfortumab vedotin before undergoing radical cystectomy, a surgical procedure to remove the bladder. Following surgery, patients received nine additional cycles of IMFINZI alone.
The combination demonstrated a 49% reduction in the risk of disease progression, recurrence, failure to undergo surgery or death compared with surgery alone or surgery followed by approved additional treatment.
At two years, an estimated 64% of patients receiving the IMFINZI combination remained alive without experiencing one of these events, compared with 45% of patients in the comparison group.
The study also demonstrated an improvement in overall survival.
Patients receiving the combination experienced a 42% lower risk of death compared with the control group. At the two-year mark, an estimated 78% of patients treated with the combination remained alive, compared with 69% in the comparison group.
Median overall survival had not been reached in either treatment group at the time of the analysis.
Dave Fredrickson, Executive Vice President of AstraZeneca’s Oncology Hematology Business Unit, said the findings support the company’s efforts to expand the use of IMFINZI in bladder cancer treatment.
“Today’s approval offers a novel IMFINZI-based regimen that almost halved the risk of disease recurrence and reduced the risk of death by 42 percent in the VOLGA trial, allowing physicians to optimize treatment for patients in this curative-intent setting. As our third bladder cancer indication in two years, this approval reinforces IMFINZI as an immunotherapy backbone across muscle-invasive and non-muscle-invasive disease.”
The treatment’s safety profile was consistent with the known risks associated with the individual medications, according to AstraZeneca.
Severe or life-threatening adverse events from any cause occurred in 64% of patients receiving the IMFINZI combination, compared with 44% in the comparison group.
During the treatment period before surgery, 24% of patients receiving the combination experienced serious adverse reactions, including urinary tract infections, rash and pneumonia.
In the postoperative treatment phase, serious adverse reactions occurred in 35% of patients receiving IMFINZI, including urinary tract infections, acute kidney injury and sepsis.
Despite these risks, researchers reported that patients receiving the combination maintained their reported quality of life following surgery.
IMFINZI is an immunotherapy designed to help the immune system recognize and attack cancer cells. The drug is already approved for several cancers, including certain forms of lung, liver, biliary tract and bladder cancer.
The latest authorization expands AstraZeneca’s bladder cancer portfolio by introducing a treatment option specifically for patients who cannot receive or have declined cisplatin-based chemotherapy.
The company is also pursuing regulatory approvals for the VOLGA treatment regimen in the European Union, Japan and other markets.
The approval follows earlier clinical advances involving IMFINZI in muscle-invasive and non-muscle-invasive bladder cancer, as AstraZeneca continues investigating the drug across different stages of the disease.


